et_marketsabout 2 hours ago
BULLISH(90%)
buy
GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy generics
Read original source+65.9
Market Impact Score
-100 Bearish+100 Bullish
AI Analysis
The Indian pharma sector is looking for new growth drivers, and the generic GLP-1 market presents a significant opportunity. This news comes amidst expectations of a challenging first half for the sector in 2026, with recovery anticipated in the second half.
Trading Insight
Maintain a bullish bias on select Indian pharma stocks with strong R&D and manufacturing capabilities for generics, focusing on those entering high-growth therapeutic areas like GLP-1s.
Quick check: SUNPHARMA bullish bias (+2.7% 1d), LUPIN bullish bias (+0.8% 1d).
Key Evidence
- •Indian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs Ozempic and Wegovy.
- •Jefferies identifies Sun Pharma, Lupin, and Torrent Pharma as potential market leaders in this segment.
- •The market for these diabetes and obesity drugs is expected to grow significantly in India.
- •Companies are adjusting supply despite initial stockouts online.
- •Risk flag: Regulatory hurdles for generic approvals
Affected Stocks
SUNPHARMASun Pharmaceutical Industries Ltd.
Positive
Identified by Jefferies as a potential market leader in generic GLP-1 drugs.
LUPINLupin Ltd.
Positive
Identified by Jefferies as a potential market leader in generic GLP-1 drugs.
TORNTPHARMTorrent Pharmaceuticals Ltd.
Positive
Identified by Jefferies as a potential market leader in generic GLP-1 drugs.
Sectors:Pharmaceuticals
AI-powered analysis by
Anadi Algo News